Viatris EBITDA 2010-2024 | VTRS

Viatris annual and quarterly EBITDA history from 2010 to 2024. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
  • Viatris EBITDA for the quarter ending June 30, 2024 was $0.546B, a 48.25% decline year-over-year.
  • Viatris EBITDA for the twelve months ending June 30, 2024 was $2.762B, a 32.85% decline year-over-year.
  • Viatris 2023 annual EBITDA was $3.507B, a 24.47% decline from 2022.
  • Viatris 2022 annual EBITDA was $4.643B, a 3.8% increase from 2021.
  • Viatris 2021 annual EBITDA was $4.473B, a 123.03% increase from 2020.
Viatris Annual EBITDA
(Millions of US $)
2023 $3,507
2022 $4,643
2021 $4,473
2020 $2,005
2019 $2,735
2018 $3,016
2017 $3,243
2016 $2,222
2015 $2,493
2014 $1,919
2013 $1,652
2012 $1,656
2011 $1,516
2010 $1,144
2009 $925
Viatris Quarterly EBITDA
(Millions of US $)
2024-06-30 $546
2024-03-31 $895
2023-12-31 $190
2023-09-30 $1,131
2023-06-30 $1,056
2023-03-31 $1,130
2022-12-31 $668
2022-09-30 $1,260
2022-06-30 $1,271
2022-03-31 $1,443
2021-12-31 $672
2021-09-30 $1,375
2021-06-30 $1,269
2021-03-31 $1,156
2020-12-31 $72
2020-09-30 $784
2020-06-30 $550
2020-03-31 $600
2019-12-31 $820
2019-09-30 $793
2019-06-30 $597
2019-03-31 $525
2018-12-31 $842
2018-09-30 $839
2018-06-30 $681
2018-03-31 $654
2017-12-31 $945
2017-09-30 $760
2017-06-30 $895
2017-03-31 $643
2016-12-31 $790
2016-09-30 $315
2016-06-30 $714
2016-03-31 $403
2015-12-31 $765
2015-09-30 $859
2015-06-30 $535
2015-03-31 $334
2014-12-31 $561
2014-09-30 $629
2014-06-30 $355
2014-03-31 $374
2013-12-31 $415
2013-09-30 $467
2013-06-30 $427
2013-03-31 $343
2012-12-31 $391
2012-09-30 $506
2012-06-30 $384
2012-03-31 $374
2011-12-31 $372
2011-09-30 $407
2011-06-30 $406
2011-03-31 $331
2010-12-31 $207
2010-09-30 $339
2010-06-30 $297
2010-03-31 $301
2009-12-31 $164
2009-09-30 $165
2009-06-30 $273
2009-03-31 $322
Sector Industry Market Cap Revenue
Medical Medical Services $13.858B $15.427B
Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.
Stock Name Country Market Cap PE Ratio
Elevance Health (ELV) United States $96.890B 12.02
Cencora (COR) United States $46.107B 17.62
DiDi Global (DIDIY) China $23.233B 0.00
ICON (ICLR) Ireland $18.679B 16.64
Revvity (RVTY) United States $15.535B 26.63
Avantor (AVTR) United States $15.498B 23.24
Natera (NTRA) United States $15.385B 0.00
BioMerieux (BMXMF) France $13.601B 0.00
Solventum (SOLV) United States $12.636B 0.00
CochLear (CHEOY) Australia $12.565B 0.00
Medpace Holdings (MEDP) United States $10.202B 28.74
Charles River Laboratories (CRL) United States $9.742B 18.41
Sonic Healthcare (SKHHY) Australia $8.273B 0.00
HealthEquity (HQY) United States $7.792B 42.29
Doximity (DOCS) United States $7.787B 49.34
Bausch + Lomb (BLCO) Canada $6.975B 32.47
Life Times (LTH) United States $4.762B 31.52
PACS (PACS) United States $4.502B 0.00
Sotera Health (SHC) United States $4.367B 23.36
Organon (OGN) United States $4.239B 4.28
Surgery Partners (SGRY) United States $3.778B 41.86
BrightSpring Health Services (BTSG) United States $3.070B 65.30
Ardent Health Partners (ARDT) United States $2.577B 0.00
Alignment Healthcare (ALHC) United States $2.546B 0.00
Concentras Parent (CON) United States $2.480B 0.00
Premier (PINC) United States $2.271B 11.34
GoodRx Holdings (GDRX) United States $2.254B 84.86
GeneDx Holdings (WGS) United States $2.057B 0.00
Ryman Healthcare (RYHTY) New Zealand $2.036B 0.00
Teladoc Health (TDOC) United States $1.575B 0.00
AMN Healthcare Services Inc (AMN) United States $1.507B 7.57
Progyny (PGNY) United States $1.425B 25.06
Establishment Labs Holdings (ESTA) $1.338B 0.00
Pediatrix Medical (MD) United States $1.319B 12.91
CareDx (CDNA) United States $1.228B 0.00
Agilon Health (AGL) United States $1.123B 0.00
Embecta (EMBC) United States $0.864B 5.76
InnovAge Holding (INNV) United States $0.822B 0.00
QDM (QDMI) Hong Kong, SAR China $0.790B 20.69
SBC Medicals (SBC) United States $0.722B 0.00
Auna S.A (AUNA) Luxembourg $0.488B 0.00
Sonida Senior Living (SNDA) United States $0.483B 0.00
Enhabit (EHAB) United States $0.382B 33.04
DocGo (DCGO) United States $0.355B 13.35
COMPASS Pathways (CMPS) United Kingdom $0.309B 0.00
Sera Prognostics (SERA) United States $0.255B 0.00
ModivCare (MODV) United States $0.232B 7.37
Beauty Health (SKIN) United States $0.211B 0.00
Biodesix (BDSX) United States $0.195B 0.00
LifeMD (LFMD) United States $0.192B 0.00
Ascend Wellness Holdings (AAWH) United States $0.178B 0.00
MultiPlan (MPLN) United States $0.136B 0.00
Nutex Health (NUTX) United States $0.127B 0.00
So-Young (SY) China $0.092B 22.35
Harvard Apparatus Regenerative Technology (HRGN) United States $0.059B 0.00
Singular Genomics Systems (OMIC) United States $0.057B 0.00
OncoCyte (OCX) United States $0.049B 0.00
NeueHealth (NEUE) United States $0.041B 1.63
Co-Diagnostics (CODX) United States $0.039B 0.00
IceCure Medical (ICCM) Israel $0.036B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.027B 0.00
Pheton Holdings (PTHL) China $0.027B 0.00
Oncology Institute (TOI) United States $0.021B 0.00
SeaStar Medical Holding (ICU) United States $0.012B 0.00
XWELL (XWEL) United States $0.009B 0.00
Intelligent Bio Solutions (INBS) United States $0.007B 0.00
BioNexus Gene Lab (BGLC) $0.007B 0.00
KindlyMD (KDLY) United States $0.005B 0.00
ISpecimen (ISPC) United States $0.004B 0.00
NewGenIvf Group (NIVF) Thailand $0.003B 0.00
Aclarion (ACON) United States $0.002B 0.00
Cano Health (CANOQ) United States $0.001B 0.00